Illustration: Lazaro Gamio/Axios

ORIC Pharmaceuticals, a developer of therapies for treatment-resistant cancers, raised $120 million in its IPO. The San Francisco-based company priced 7.5 million shares at $16, versus initial plans to sell 5 million shares at between $14-$16, giving it an initial market cap of $441 million.

Why it matters: This reflects how the IPO market remains open for biotech startups and SPACs, likely because neither type of issuer has any revenue to lose from pandemic closures.

  • ROI: ORIC had raised $173 million in VC funding from firms like The Column Group (22.4% pre-IPO stake), Topspin Fund (15.6%), OrbiMed (11.7%), and EcoR1 Capital (5.8%).

The bottom line: "The discovery of ORIC’s lead experimental drug stemmed from work done by co-founder Charles Sawyers. Previously Sawyers was involved in the discovery of enzalutamide, which aims seeks to slow tumor cell growth by blocking androgens from binding with the androgen receptor. (Androgens, male sex hormones, prompt prostate cancer cell growth.) Another company co-founder, Scott Lowe, is a colleague of Sawyers and an expert in tumor networks and the factors in cancer cells’ response to treatment." — Sarah de Crescenzo, Xconomy

Go deeper: Meet the startups that have raised more than $1 billion

Go deeper

Deadly Hurricane Zeta slams U.S. Gulf Coast

A satellite image of Hurricane Zeta. Photo: National Hurricane Center/NOAA

Hurricane Zeta has killed at least one person after a 55-year-old man was "electrocuted by a downed power line" in Louisiana as the storm caused widespread power outages Wednesday night, per AP.

What's happening: Zeta made landfall south of New Orleans as a Category 2 hurricane earlier Wednesday before weakening to Category 1. But it was still "battering southeastern Louisiana and southern Mississippi with life-threatening storm surge, high winds, and heavy rain" late Wednesday, per the National Hurricane Center.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Politics: Biden ahead in Wisconsin, Michigan as cases surge in the Midwest.
  2. Health: Fauci says U.S. may not return to normal until 2022 — Trump's testing czar: Surge "is real" and not just caused by more tests Some coronavirus survivors have "autoantibodies."
  3. Business: Consumer confidence sinking Testing is a windfall.
  4. World: Europe faces "stronger and deadlier" wave France imposes lockdown Germany to close bars and restaurants for a month.
  5. Sports: Boston Marathon delayed MLB to investigate Dodgers player who joined celebration after positive COVID test.
2 hours ago - Health

Fauci says U.S. may not return to normal until 2022

Director of the National Institute of Allergy and Infectious Diseases, Anthony Fauci, testifies during a September Senate hearing on COVID-19 in Washington, D.C. Photo: Graeme Jennings/Pool/AFP via Getty Images

NIAID director Anthony Fauci told the Journal of the American Medical Association on Wednesday he doesn't expect a COVID-19 vaccine to be ready until January 2021 or later.

What he's saying: Fauci said during the interview that the U.S. was in a "bad position" after failing to keep case numbers down post-summer. "We should have been way down in baseline and daily cases and we’re not," he said.